Last reviewed 2026-05-27 · How we verify

Tienoridine (TINORIDINE)

Phase 3 active Small molecule ✓ Verified May 2026

Tienoridine (generic name: TINORIDINE) is a tinoridine drug. It is currently in Phase 3 development for Pain.

Tienoridine works by binding to the adenosine receptor A1, which helps to reduce pain by modulating the activity of neurons.

Tienoridine is a small molecule with the synonyms NSC-158555, TINORIDINA, TINORIDINE, TINORIDINE, Y 3642, and Y-3642.

Likelihood of approval

55.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TINORIDINE
Drug class	tinoridine
Target	Adenosine receptor A1
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 3

Mechanism of action

Imagine your brain is like a busy city, and the adenosine receptor A1 is like a traffic light that helps control the flow of information between different parts of the city. When Tienoridine binds to this receptor, it helps to slow down the flow of pain signals, making it easier to manage pain. This can be especially helpful for people who are experiencing chronic pain.

Approved indications

Pain

Common side effects

No common side effects on file.

Key clinical trials

Efficacy of Tinoridine in Treating Pain and Inflammation in Adults (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tienoridine CI brief — competitive landscape report
Tienoridine updates RSS · CI watch RSS

Frequently asked questions about Tienoridine

What is Tienoridine?

Tienoridine (TINORIDINE) is a tinoridine drug, indicated for Pain.

How does Tienoridine work?

Tienoridine works by binding to the adenosine receptor A1, which helps to reduce pain by modulating the activity of neurons.

What is Tienoridine used for?

Tienoridine is indicated for Pain.

What is the generic name of Tienoridine?

TINORIDINE is the generic (nonproprietary) name of Tienoridine.

What drug class is Tienoridine in?

Tienoridine belongs to the tinoridine class. See all tinoridine drugs at /class/tinoridine.

What development phase is Tienoridine in?

Tienoridine is in Phase 3.

What does Tienoridine target?

Tienoridine targets Adenosine receptor A1 and is a tinoridine.

Drug class: All tinoridine drugs
Target: All drugs targeting Adenosine receptor A1
Therapeutic area: All drugs in Neuroscience
Indication: Drugs for Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing